METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo drug may shrink fatty liver in diabetics
Disease control ENROLLING_BY_INVITATIONThis study compares two diabetes treatments—a combination drug (iGlarLixi) versus insulin alone—to see which better reduces liver fat in people with type 2 diabetes and fatty liver disease. About 36 participants will take the assigned medication for 12 weeks. The goal is to find …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: PHASE4 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New drug shows promise against fatty liver cirrhosis
Disease control OngoingThis study tests an experimental drug called efinopegdutide in 80 adults with liver scarring (cirrhosis) caused by a type of fatty liver disease (MASH). The goal is to see if the drug can lower liver fat, inflammation, and scarring over about 7 months. Participants will receive e…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Can a simple step-by-step program help fight fatty liver? new study seeks answers.
Disease control OngoingThis study tests whether a weight loss program called "Paso a Paso" is practical for 50 Mexican and Central American adults with fatty liver disease and overweight. Researchers will check if participants attend enough sessions and if the program helps with weight loss, liver heal…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New ultrasound could replace needle biopsy for kids with fatty liver
Diagnosis OngoingThis study checks if a special ultrasound called Velacur can accurately detect fatty liver disease (MASLD) in children aged 2 to 20. About 200 kids will get the quick, painless scan, and results will be compared to MRI or liver biopsy. The goal is to find a safer, faster way to d…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Emory University • Aim: Diagnosis
Last updated May 22, 2026 13:54 UTC
-
New MRI scan could replace painful liver biopsies for MASH patients
Diagnosis ENROLLING_BY_INVITATIONThis study aims to see if a special MRI scan can accurately detect liver scarring (fibrosis) in people with a fatty liver disease called MASH. Researchers will compare the MRI results with standard tests like ultrasound and blood work. If successful, this could offer a noninvasiv…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated May 18, 2026 12:03 UTC
-
App attack on fatty liver: new study tests digital weight loss for HIV patients
Symptom relief ENROLLING_BY_INVITATIONThis study tests if a mobile app providing personalized lifestyle coaching can help people living with HIV and fatty liver disease lose at least 5% of their body weight. About 116 adults will be randomly assigned to use the app or receive standard healthy living advice. The goal …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated May 26, 2026 05:47 UTC
-
Major study aims to end painful liver biopsies for fatty liver patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1,689 adults with fatty liver disease (MASLD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression and predict serious liver problems. Researchers hope these scans could replace liver biopsies in future drug studies and r…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Sponsor: HRI-MAIL-NIT • Aim: Knowledge-focused
Last updated May 26, 2026 05:46 UTC